⚠ Unsupported Browser ⚠ Our site probably won't work so great in Internet Explorer. Please try a more recent version of a major browser like Chrome, Firefox, Safari, or Edge.
REMOVAL international multicentre trial.

Reversing with Metformin Vascular Adverse Lesions (REMOVAL)

People with Type 1 diabetes are at increased risk of atherosclerosis (hardening of the arteries), which can lead to heart attacks, stroke and amputation. Paralleling the general population more people with Type 1 diabetes are overweight or obese, which is associated with the development of some feature such as insulin resistance and lipid (blood fat) problems more commonly associated with Type 2 diabetes. Because of this many groups are exploring the addition of glucose control treatments usually used in Type 2 diabetes care to the essential insulin for Type 1 diabetes. High heart disease risk adults with Type 1 diabetes were prescribed metformin vs. placebo for a mean of 3-years. Metformin was associated with slowing of artery damage (in the carotid arteries in the neck) and also reduced progression of kidney damage.

Relevant Publications